Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on April 12, 2021. The report details the completion of a previously announced underwritten public offering of common stock for its subsidiary, Eton Pharmaceuticals, Inc.
Key Financial Metrics
The filing reports the following transaction-specific financial data:
- Shares Issued: 1,518,000 shares of Eton Pharmaceuticals, Inc. common stock.
- Offering Price: $7.00 per share.
- Gross Proceeds: Approximately $10.6 million.
- Net Proceeds: Not specified; gross proceeds are before underwriting discounts, commissions, and offering expenses.
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for Harrow Health, Inc. as a whole.
Material Changes
The primary material change is the successful closing of the equity offering for Eton Pharmaceuticals, Inc. This includes the full exercise of the underwriter's over-allotment option, resulting in the issuance of an additional 198,000 shares beyond the initial offering size.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to this transaction. The document strictly reports the completion of the asset disposition/acquisition event under Item 2.01.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the impact of the 1,518,000 new shares on the total outstanding share count of Eton Pharmaceuticals, Inc.
- Review the use of proceeds as disclosed in the related prospectus or registration statement.
- Check for any subsequent filings regarding the integration of Eton Pharmaceuticals or changes in Harrow Health's consolidated financial position.